NASDAQ:FBLG FibroBiologics (FBLG) Stock Price, News & Analysis $0.63 +0.01 (+2.06%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About FibroBiologics Stock (NASDAQ:FBLG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FibroBiologics alerts:Sign Up Key Stats Today's Range$0.62▼$0.6450-Day Range$0.53▼$0.7552-Week Range$0.53▼$4.41Volume96,418 shsAverage Volume343,175 shsMarket Capitalization$26.52 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company Overview FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas. Read More FibroBiologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreFBLG MarketRank™: FibroBiologics scored higher than 53% of companies evaluated by MarketBeat, and ranked 527th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingFibroBiologics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFibroBiologics has only been the subject of 2 research reports in the past 90 days.Read more about FibroBiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for FibroBiologics are expected to grow in the coming year, from ($0.53) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroBiologics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroBiologics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFibroBiologics has a P/B Ratio of 31.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about FibroBiologics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.47% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroBiologics has recently increased by 42.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFibroBiologics does not currently pay a dividend.Dividend GrowthFibroBiologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.47% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroBiologics has recently increased by 42.35%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.94 News SentimentFibroBiologics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for FibroBiologics this week, compared to 2 articles on an average week.Search Interest20 people have searched for FBLG on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows8 people have added FibroBiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, FibroBiologics insiders have not sold or bought any company stock.Percentage Held by Insiders20.00% of the stock of FibroBiologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about FibroBiologics' insider trading history. Receive FBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroBiologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FBLG Stock News HeadlinesFibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 27 at 8:30 AM | globenewswire.comFibroBiologics (FBLG) and Its Competitors Head to Head ContrastAugust 19, 2025 | americanbankingnews.comOvernight moves = possibly bigger returnsHere’s a chart everyone should see that dates back to 1993… As you can see, the top line shows the much bigger average market return from trading overnight… Versus the bottom line, which shows the more modest average return from trading during the day. Look at that gigantic difference! So if you prefer nice big overnight returns instead, I agree with you. That’s why I’ve designed a breakthrough trade to tap into that overnight trading frenzy. You can check that out right here. Obviously, I won’t make any reckless guarantees in the stock market, but… That eye-opening chart above is just the beginning of the benefits you’ll see to trading overnight. PLUS, you’ll also see what my #1 ranked asset is in the entire market… And what my “hands-off” stocks are that I wouldn’t touch with a 100-foot pole.August 29 at 2:00 AM | ProsperityPub (Ad)FBLG: Closes Third Tranche of $5M…August 5, 2025 | msn.comFibroBiologics, Inc.: FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 1, 2025 | finanznachrichten.deFibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateJuly 31, 2025 | globenewswire.comFibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical ApplicationsJuly 28, 2025 | globenewswire.comBrag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJuly 11, 2025 | usatoday.comSee More Headlines FBLG Stock Analysis - Frequently Asked Questions How have FBLG shares performed this year? FibroBiologics' stock was trading at $2.00 on January 1st, 2025. Since then, FBLG stock has decreased by 69.0% and is now trading at $0.6202. How were FibroBiologics' earnings last quarter? FibroBiologics Inc. (NASDAQ:FBLG) posted its quarterly earnings data on Thursday, July, 31st. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. When did FibroBiologics IPO? FibroBiologics (FBLG) raised $144 million in an IPO on Wednesday, January 31st 2024. The company issued 4,806,226 shares at a price of $30.00 per share. Who are FibroBiologics' major shareholders? Top institutional shareholders of FibroBiologics include Cascade Financial Partners LLC (0.69%), Geode Capital Management LLC (0.69%), Cerity Partners LLC (0.31%) and Jane Street Group LLC (0.23%). View institutional ownership trends. How do I buy shares of FibroBiologics? Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of FibroBiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroBiologics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Netflix (NFLX). Company Calendar Last Earnings7/31/2025Today8/29/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FBLG Previous SymbolNASDAQ:FBLG CIK1958777 Webwww.fibrobiologics.com Phone281-671-5150FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for FibroBiologics$13.00 High Price Target$16.00 Low Price Target$12.00 Potential Upside/Downside+1,996.1%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-710.25% Return on Assets-118.02% Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book31.01Miscellaneous Outstanding Shares41,890,000Free Float33,511,000Market Cap$25.98 million OptionableN/A Beta-0.74 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:FBLG) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.